Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shenzhu Tiaopi granule is a Traditional Chinese Medicine (TCM) formulation primarily investigated for its role in community-based diabetes intervention and the management of impaired glucose tolerance. Developed and studied by researchers at The First Affiliated Hospital of Anhui University of Chinese Medicine, the granule is intended to regulate spleen function—a core concept in TCM for managing metabolic health—thereby improving glucose metabolism and preventing the progression to type 2 diabetes. It is typically administered orally as part of a comprehensive intervention strategy that includes lifestyle modifications.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Shenzhu Tiaopi granule.